{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:54:12Z","timestamp":1793231652639,"version":"4.5.0"},"reference-count":94,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T00:00:00Z","timestamp":1621555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.drudis.2021.05.008","type":"journal-article","created":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T12:51:48Z","timestamp":1621601508000},"page":"2367-2376","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":190,"title":["Drug combination therapy for emerging viral diseases"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8710-9938","authenticated-orcid":false,"given":"Zeenat A.","family":"Shyr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Shan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald C.","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1034-0757","authenticated-orcid":false,"given":"Wei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2021.05.008_b0005","unstructured":"1918 Pandemic. Centers for Disease Control and Prevention Website. www.cdc.gov\/flu\/pandemic-resources\/1918-pandemic-h1n1.html. Updated March 20 2019 [Accessed May 14, 2021]"},{"key":"10.1016\/j.drudis.2021.05.008_b0010","unstructured":"Severe Acute Respiratory Syndrome. Centers for Disease Control and Prevention Website. www.cdc.gov\/sars\/about\/fs-sars.html\/. Updated December 6, 2017. [Accessed May 14, 2021]"},{"key":"10.1016\/j.drudis.2021.05.008_b0015","unstructured":"Middle East Respiratory Syndrome Virus. WHO Website. www.who.int\/news-room\/fact-sheets\/detail\/middle-east-respiratory-syndrome-coronavirus-(mers-cov). Updated March 11, 2019. [Accessed May 14, 2021]"},{"key":"10.1016\/j.drudis.2021.05.008_b0020","unstructured":"Ebola Virus Disease. WHO Website. www.who.int\/en\/news-room\/fact-sheets\/detail\/ebola-virus-disease. Updated February 23, 2021. [Accessed May 14, 2021]"},{"key":"10.1016\/j.drudis.2021.05.008_b0025","unstructured":"Ebola Virus Disease. Centers for Disease Control and Prevention Website. www.cdc.gov\/vhf\/ebola\/clinicians\/vaccine\/index.html. Updated February 25, 2021. [Accessed May 14, 2021]"},{"issue":"suppl_10","key":"10.1016\/j.drudis.2021.05.008_b0030","doi-asserted-by":"crossref","first-page":"S860","DOI":"10.1093\/infdis\/jix451","article-title":"History and emergence of Zika virus","volume":"216","author":"Gubler","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.drudis.2021.05.008_b0035","unstructured":"Coronavirus Resource Center. Johns Hopkins University Website. https:\/\/coronavirus.jhu.edu\/map.html. Updated April 14, 2021. [Accessed May 14, 2021]"},{"key":"10.1016\/j.drudis.2021.05.008_b0040","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nmeth.4365","article-title":"Probes & Drugs portal: an interactive, open data resource for chemical biology","volume":"14","author":"Skuta","year":"2017","journal-title":"Nat Methods"},{"key":"10.1016\/j.drudis.2021.05.008_b0045","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.ymthe.2020.12.016","article-title":"Synergistic and antagonistic drug combinations against SARS-CoV-2","volume":"29","author":"Bobrowski","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.drudis.2021.05.008_b0050","unstructured":"Cancer Trends Progress Report. National Cancer Institute. https:\/\/progressreport.cancer.gov\/ [Accessed May 14, 2021]"},{"key":"10.1016\/j.drudis.2021.05.008_b0055","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1056\/NEJMp038194","article-title":"The discovery of HIV as the cause of AIDS","volume":"349","author":"Gallo","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2021.05.008_b0060","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/0022034511399082","article-title":"Therapy for HIV: past, present, and future","volume":"23","author":"Peters","year":"2011","journal-title":"Adv Dent Res"},{"issue":"Suppl. 3","key":"10.1016\/j.drudis.2021.05.008_b0065","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/hiv.12952","article-title":"Managing HIV-associated inflammation and ageing in the era of modern ART","volume":"21","author":"Bloch","year":"2020","journal-title":"HIV Med"},{"key":"10.1016\/j.drudis.2021.05.008_b0070","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1056\/NEJM198707233170401","article-title":"The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial","volume":"317","author":"Fischl","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2021.05.008_b0075","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1517\/14656566.2012.642865","article-title":"Combination nucleoside\/nucleotide reverse transcriptase inhibitors for treatment of HIV infection","volume":"13","author":"Akanbi","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.drudis.2021.05.008_b0080","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.coviro.2016.03.004","article-title":"Current status and prospects of HIV treatment","volume":"18","author":"Cihlar","year":"2016","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.drudis.2021.05.008_b0085","unstructured":"Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV Website. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv\/what-start-initial-combination-regimens-antiretroviral-naive. Updated December 18, 2019. [Accessed May 14, 2021]"},{"key":"10.1016\/j.drudis.2021.05.008_b0090","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/phar.1728","article-title":"Impact of pill burden on adherence, risk of hospitalization, and viral suppression in patients with HIV Infection and AIDS receiving antiretroviral therapy","volume":"36","author":"Scott Sutton","year":"2016","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.drudis.2021.05.008_b0095","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12981-020-00268-1","article-title":"Real-world adherence and persistence for newly-prescribed HIV treatment: single versus multiple tablet regimen comparison among US Medicaid beneficiaries","volume":"17","author":"Cohen","year":"2020","journal-title":"AIDS Res Ther"},{"key":"10.1016\/j.drudis.2021.05.008_b0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0081355","article-title":"Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada","volume":"8","author":"Samji","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.drudis.2021.05.008_b0105","article-title":"Treatment of hepatitis C virus infection","author":"Parlati","year":"2020","journal-title":"Clin Res Hepatol Gastroenterol. Published online November 30"},{"key":"10.1016\/j.drudis.2021.05.008_b0110","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.coviro.2020.10.002","article-title":"Immune system control of hepatitis C virus infection","volume":"46","author":"Stuart","year":"2020","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.drudis.2021.05.008_b0115","unstructured":"Hepatitis C. WHO Website. www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c. Updated July 27, 2020. [Accessed May 14, 2021]"},{"key":"10.1016\/j.drudis.2021.05.008_b0120","unstructured":"Viral Hepatitis and Liver Disease. US Department of Veterans Affairs Website. www.hepatitis.va.gov. Updated January 7, 2021. [Accessed May 14, 2021]"},{"key":"10.1016\/j.drudis.2021.05.008_b0125","first-page":"316","article-title":"Hepatitis C in a new era: a review of current therapies","volume":"42","author":"Kish","year":"2017","journal-title":"P T"},{"key":"10.1016\/j.drudis.2021.05.008_b0130","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/B978-0-12-405880-4.00005-6","article-title":"Hepatitis C virus: standard-of-care treatment","volume":"67","author":"Pawlotsky","year":"2013","journal-title":"Adv Pharmacol"},{"key":"10.1016\/j.drudis.2021.05.008_b0135","unstructured":"Recommendations for testing managing and treating hepatitis C. AASLD\/IDSA HCV guidance panel website. http:\/\/hcvguidelines.org. Updated August 27, 2020. [Accessed May 14, 2021]"},{"key":"10.1016\/j.drudis.2021.05.008_b0140","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(14)61228-9","article-title":"Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study","volume":"385","author":"Kohli","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2021.05.008_b0145","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","article-title":"Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection","volume":"376","author":"Bourli\u00e8re","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2021.05.008_b0150","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.jhep.2018.07.023","article-title":"No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients","volume":"69","author":"Sarrazin","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.drudis.2021.05.008_b0155","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/jvh.13115","article-title":"Real-world effectiveness of sofosbuvir\/velpatasvir\/voxilaprevir in 573 direct-acting antiviral experienced hepatitis C patients","volume":"26","author":"Belperio","year":"2019","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.drudis.2021.05.008_b0160","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1007\/s00705-020-04639-x","volume":"165","author":"Said","year":"2020","journal-title":"Arch Virol"},{"key":"10.1016\/j.drudis.2021.05.008_b0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0224875","article-title":"HIV\/HCV therapy with ledipasvir\/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens","volume":"15","author":"Huhn","year":"2020","journal-title":"PLoS ONE"},{"key":"10.1016\/j.drudis.2021.05.008_b0170","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2147\/IDR.S105473","article-title":"Drug resistance in influenza A virus: the epidemiology and management","volume":"10","author":"Hussain","year":"2017","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.drudis.2021.05.008_b0175","unstructured":"Influenza. Centers for Disease Control and Prevention website. www.cdc.gov\/flu\/vaccines-work\/effectiveness-studies.htm. Updated December 11, 2020. [Accessed May 14, 2021]"},{"key":"10.1016\/j.drudis.2021.05.008_b0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0009332","article-title":"Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro","volume":"5","author":"Nguyen","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.drudis.2021.05.008_b0185","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.3389\/fphar.2018.01207","article-title":"Investigating different mechanisms of action in combination therapy for influenza","volume":"9","author":"Melville","year":"2018","journal-title":"Front Pharmacol."},{"key":"10.1016\/j.drudis.2021.05.008_b0190","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1093\/infdis\/jis265","article-title":"Combination antiviral therapy for influenza: predictions from modeling of human infections","volume":"205","author":"Perelson","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.drudis.2021.05.008_b0195","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1093\/infdis\/jiz656","article-title":"Comparative effectiveness of combined favipiravir and oseltamivir therapy versus oseltamivir monotherapy in critically ill patients with influenza virus infection","volume":"221","author":"Wang","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.drudis.2021.05.008_b0200","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.biologicals.2017.08.007","article-title":"A phase 1 study to evaluate the safety and pharmacokinetics of MEDI8852, an anti-influenza A monoclonal antibody, in healthy adult volunteers","volume":"50","author":"Mallory","year":"2017","journal-title":"Biologicals"},{"key":"10.1016\/j.drudis.2021.05.008_b0205","doi-asserted-by":"crossref","first-page":"e00694","DOI":"10.1128\/AAC.00694-18","article-title":"Evaluation of MEDI8852, an anti-influenza A monoclonal antibody, in treating acute uncomplicated influenza","volume":"62","author":"Ali","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.drudis.2021.05.008_b0210","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.ebiom.2018.12.051","article-title":"Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: results from a randomized, double-blind, phase-2, placebo-controlled study","volume":"40","author":"Hershberger","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.drudis.2021.05.008_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104763","article-title":"Clinical and virological responses to a broad-spectrum human monoclonal antibody in an influenza virus challenge study","volume":"184","author":"Sloan","year":"2020","journal-title":"Antiviral Res"},{"key":"10.1016\/j.drudis.2021.05.008_b0220","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2021.05.008_b0225","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"A randomized, controlled trial of Ebola virus disease therapeutics","volume":"381","author":"Mulangu","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2021.05.008_b0230","unstructured":"Shyr ZA, Cheng Y, Zheng W. Drug combinations. In: Kenakin T, ed. Comprehensive Pharmacology. Oxford: Elsevier (in press)."},{"key":"10.1016\/j.drudis.2021.05.008_b0235","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/nbt.2391","article-title":"Systematic identification of synergistic drug pairs targeting HIV","volume":"30","author":"Tan","year":"2012","journal-title":"Nat Biotechnol"},{"issue":"3","key":"10.1016\/j.drudis.2021.05.008_b0240","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1744-7348.1939.tb06990.x","article-title":"The toxicity of poisons applied jointly 1","volume":"26","author":"Bliss","year":"1939","journal-title":"Ann Appl Biol"},{"key":"10.1016\/j.drudis.2021.05.008_b0245","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0031-6997(25)00026-2","article-title":"What is synergy?","volume":"41","author":"Berenbaum","year":"1989","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.drudis.2021.05.008_b0255","doi-asserted-by":"crossref","first-page":"7301","DOI":"10.1158\/1078-0432.CCR-17-1121","article-title":"Matrix screen identifies synergistic combination of PARP inhibitors and nicotinamide phosphoribosyltransferase (NAMPT) inhibitors in Ewing sarcoma","volume":"23","author":"Heske","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2021.05.008_b0260","first-page":"65","article-title":"Consensus on concepts and terminology for combined action assessment: the Saariselk\u00e4 agreement","volume":"4","author":"Greco","year":"1992","journal-title":"Arch Complex Environ Stud"},{"key":"10.1016\/j.drudis.2021.05.008_b0265","first-page":"181","article-title":"What is synergy?","volume":"6","author":"Tang","year":"2015","journal-title":"The Saariselka agreement revisited. Front Pharmacol."},{"key":"10.1016\/j.drudis.2021.05.008_b0270","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.149","article-title":"Analysis of drug combinations: current methodological landscape","volume":"3","author":"Foucquier","year":"2015","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.drudis.2021.05.008_b0275","doi-asserted-by":"crossref","first-page":"E237","DOI":"10.1152\/ajpendo.00308.2012","article-title":"Understanding synergy","volume":"304","author":"Geary","year":"2013","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.drudis.2021.05.008_b0280","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.tips.2020.01.011","article-title":"Charting the fragmented landscape of drug synergy","volume":"41","author":"Meyer","year":"2020","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.drudis.2021.05.008_b0285","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1016\/j.drudis.2019.09.002","article-title":"Applying synergy metrics to combination screening data: agreements, disagreements and pitfalls","volume":"24","author":"Vlot","year":"2019","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2021.05.008_b0290","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.antiviral.2016.11.017","article-title":"Synergistic drug combination effectively blocks Ebola virus infection","volume":"137","author":"Sun","year":"2017","journal-title":"Antiviral Res"},{"key":"10.1016\/j.drudis.2021.05.008_b0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.disamonth.2020.101053","article-title":"Middle East Respiratory Syndrome (MERS) Coronavirus","volume":"66","author":"McFee","year":"2020","journal-title":"Dis Mon"},{"key":"10.1016\/j.drudis.2021.05.008_b0300","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/nm.4184","article-title":"Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen","volume":"22","author":"Xu","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.drudis.2021.05.008_b0305","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41421-018-0034-1","article-title":"Emetine inhibits Zika and Ebola virus infections through two molecular mechanisms: inhibiting viral replication and decreasing viral entry","volume":"4","author":"Yang","year":"2018","journal-title":"Cell Discov"},{"key":"10.1016\/j.drudis.2021.05.008_b0310","article-title":"Experimental treatment with favipiravir for Ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea","volume":"13","author":"Sissoko","year":"2016","journal-title":"PLoS Med"},{"key":"10.1016\/j.drudis.2021.05.008_b0315","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1056\/NEJMe1915350","article-title":"Monoclonal antibody therapy for Ebola virus disease","volume":"381","author":"Levine","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2021.05.008_b0320","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2 - preliminary report","volume":"383","author":"Jackson","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2021.05.008_b0325","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa2028436","article-title":"Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults","volume":"383","author":"Anderson","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2021.05.008_b0330","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2021.05.008_b0335","unstructured":"Emerging SARS-CoV-2 Variants. Centers for Disease Control and Prevention Website. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/more\/science-and-research\/scientific-brief-emerging\u2013variants.html. Updated January 28, 2021. [Accessed May 14, 2021]"},{"key":"10.1016\/j.drudis.2021.05.008_b0340","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res"},{"key":"10.1016\/j.drudis.2021.05.008_b0345","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed antiviral drugs for Covid-19 - interim WHO Solidarity Trial results","volume":"384","author":"WHO Solidarity Trial Consortium","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2021.05.008_b0350","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2021.05.008_b0355","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19 - final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2021.05.008_b0360","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.cmi.2020.08.005","article-title":"Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks","volume":"26","author":"Wooding","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.drudis.2021.05.008_b0365","first-page":"133","article-title":"Dexamethasone in hospitalized patients with Covid-19 \u2013 preliminary report","volume":"58","author":"RECOVERY Collaborative Group","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2021.05.008_b0370","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2021.05.008_b0375","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.2020.17021","article-title":"Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial","volume":"324","author":"Tomazini","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.drudis.2021.05.008_b0380","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(20)31042-4","article-title":"Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial","volume":"395","author":"Hung","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2021.05.008_b0385","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus remdesivir for hospitalized adults with Covid-19","volume":"384","author":"Kalil","year":"2021","journal-title":"N Engl J Med"},{"issue":"suppl_5","key":"10.1016\/j.drudis.2021.05.008_b0390","doi-asserted-by":"crossref","first-page":"S672","DOI":"10.1093\/infdis\/jiy304","article-title":"Identification of combinations of approved drugs with synergistic activity against Ebola virus in cell cultures","volume":"218","author":"Dyall","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.drudis.2021.05.008_b0395","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3390\/v10060283","article-title":"Saracatinib inhibits Middle East respiratory syndrome-coronavirus replication in vitro","volume":"10","author":"Shin","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.drudis.2021.05.008_b0400","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1021\/acsmedchemlett.0c00316","article-title":"Advantages of the parent nucleoside GS-441524 over remdesivir for Covid-19 treatment","volume":"11","author":"Yan","year":"2020","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.drudis.2021.05.008_b0405","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41586-021-03312-w","article-title":"SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801","volume":"591","author":"Wahl","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2021.05.008_b0410","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41564-020-00835-2","article-title":"Therapeutically administered ribonucleoside analogue MK-4482\/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets","volume":"6","author":"Cox","year":"2021","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.drudis.2021.05.008_b0415","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.it.2020.04.004","article-title":"Opportunities for small molecules in cancer immunotherapy","volume":"41","author":"van der Zanden","year":"2020","journal-title":"Trends Immunol"},{"key":"10.1016\/j.drudis.2021.05.008_b0420","unstructured":"COVID-19. Centers for Disease Control and Prevention Website. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/hcp\/clinical-guidance-management-patients.html. Updated February 16, 2021. [Accessed May 14, 2021]"},{"key":"10.1016\/j.drudis.2021.05.008_b0425","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3389\/fchem.2019.00509","article-title":"Predicting synergism of cancer drug combinations using NCI-ALMANAC data","volume":"7","author":"Sidorov","year":"2019","journal-title":"Front Chem"},{"key":"10.1016\/j.drudis.2021.05.008_b0430","article-title":"Rapid identification of potential inhibitors of SARS-CoV\u20132 main protease by deep docking of 1.3 billion compounds. Mol","volume":"39","author":"Ton","year":"2020","journal-title":"Inform"},{"key":"10.1016\/j.drudis.2021.05.008_b0435","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41421-020-0153-3","article-title":"Network-based drug repurposing for novel coronavirus 2019-nCoV\/SARS-CoV-2","volume":"6","author":"Zhou","year":"2020","journal-title":"Cell Discov."},{"key":"10.1016\/j.drudis.2021.05.008_b0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104490","article-title":"Computational drug discovery and repurposing for the treatment of COVID-19: a systematic review","volume":"106","author":"Mohamed","year":"2021","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.drudis.2021.05.008_b0445","doi-asserted-by":"crossref","first-page":"e667","DOI":"10.1016\/S2589-7500(20)30192-8","article-title":"Artificial intelligence in COVID-19 drug repurposing","volume":"2","author":"Zhou","year":"2020","journal-title":"Lancet Digit Health"},{"key":"10.1016\/j.drudis.2021.05.008_b0450","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.drudis.2018.08.010","article-title":"Advancing precision medicine with personalized drug screening","volume":"24","author":"Gorshkov","year":"2019","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2021.05.008_b0455","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41586-020-2312-y","article-title":"The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice","volume":"583","author":"Bao","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2021.05.008_b0460","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1038\/s41590-020-0778-2","article-title":"SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function","volume":"21","author":"Winkler","year":"2020","journal-title":"Nat Immunol"},{"key":"10.1016\/j.drudis.2021.05.008_b0465","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.cell.2020.05.027","article-title":"Pathogenesis of SARS-CoV-2 in transgenic mice expressing human angiotensin-converting enzyme 2","volume":"182","author":"Jiang","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2021.05.008_b0470","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41586-020-2787-6","article-title":"Animal models for COVID-19","volume":"586","author":"Mu\u00f1oz-Fontela","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2021.05.008_b0475","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1124\/jpet.120.000123","article-title":"Drug discovery strategies for SARS-CoV-2","volume":"375","author":"Shyr","year":"2020","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644621002403?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644621002403?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:55:17Z","timestamp":1761224117000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644621002403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":94,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S1359644621002403"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2021.05.008","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug combination therapy for emerging viral diseases","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2021.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}